A Multicenter Phase I Clinical Study of CD19-Targeted CAR-NK Cell Therapy for Moderate to Severe Active Systemic Lupus Erythematosus in China
Latest Information Update: 30 Jan 2026
At a glance
- Drugs KN 5501 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms CLEAR
- Sponsors Rui Therapeutics
Most Recent Events
- 30 Jan 2026 New trial record